Bipolar Disorder vs Depression (MDD) — Clinical Trial Comparison
Bipolar Disorder
Alternating episodes of mania and depression
Depression (MDD)
Persistent low mood and loss of interest
Bipolar disorder and major depressive disorder (MDD) share depressive episodes but are fundamentally different conditions with distinct trial landscapes. Bipolar trials focus on mood stabilisers and manic episode prevention, while MDD trials concentrate on antidepressant innovation and treatment-resistant approaches. Accurate diagnosis is critical because some antidepressants can trigger manic episodes in bipolar patients.
Key Differences at a Glance
| Feature | Bipolar Disorder | Depression (MDD) |
|---|---|---|
| Primary symptoms | Mania/hypomania + depressive episodes | Persistent low mood, anhedonia, fatigue |
| Diagnostic key | At least one manic/hypomanic episode | No history of mania or hypomania |
| Severity scoring | YMRS (mania), MADRS/PHQ-9 (depression) | PHQ-9, MADRS, HAM-D |
| NICE first-line | Lithium or valproate + psychotherapy | CBT + SSRI/SNRI |
| Course pattern | Episodic with normal periods between | Can be episodic or chronic |
| Co-occurrence rate | ~50% also have anxiety disorder | ~50% also have anxiety disorder |
Clinical Trial Availability
| Trial Aspect | Bipolar Disorder | Depression (MDD) |
|---|---|---|
| UK trials actively recruiting | 30–50 studies | 80–130 studies |
| Most common trial phase | Phase 2–3 | Phase 2–3 |
| Top interventions tested | Mood stabilisers, antipsychotics, chronotherapy, neuromodulation | Novel antidepressants, psychedelics, neuromodulation, digital therapeutics |
| Psychedelic trials | Limited (psilocybin exploratory) | Psilocybin (multiple UK sites) |
| Treatment-resistant focus | Less common category | Major trial category |
| Prevention trials | Relapse prevention major focus | Relapse prevention moderate focus |
Exciting Emerging Treatments
Bipolar Disorder Trials
- Novel mood stabilisers — next-generation lithium alternatives with fewer side effects
- Chronotherapy — light therapy, sleep phase advance for bipolar depression
- Antipsychotic long-acting injectables — improved adherence for maintenance
- Neuromodulation — TMS and tDCS for bipolar depression episodes
- Digital phenotyping — smartphone-based mood episode prediction
- Anti-inflammatory agents — targeting neuroinflammation in mood episodes
Depression (MDD) Trials
- Psilocybin-assisted therapy — multiple UK trials, including treatment-resistant depression
- Ketamine/esketamine — rapid-acting for TRD, nasal spray and IV formulations
- Transcranial Magnetic Stimulation (TMS) — non-invasive brain stimulation
- Novel glutamate modulators — targeting NMDA receptors
- Orexin receptor antagonists — dual antidepressant + sleep benefit
- Digital therapeutics — app-delivered CBT and behavioural activation
💡 Misdiagnosis is common — and it matters for trials
Up to 20% of people diagnosed with depression actually have bipolar disorder. This distinction is critical because standard antidepressants can trigger manic episodes in bipolar patients, and many MDD trials exclude anyone with bipolar history. If your depression has involved periods of elevated mood, decreased need for sleep, or racing thoughts, ask your psychiatrist about bipolar screening before considering trials.
Eligibility Differences
Bipolar Disorder Trial Criteria
- Clear bipolar I or II diagnosis required (DSM-5/ICD-11 criteria)
- Current mood state matters — some trials require euthymic, others acute mania or depression
- Mania-specific trials may require YMRS ≥ 20
- Bipolar depression trials typically exclude current manic/hypomanic symptoms
- Medication washout periods may be shorter than MDD trials due to relapse risk
- History of rapid cycling may be inclusion or exclusion depending on trial
Depression (MDD) Trial Criteria
- Minimum severity score required (PHQ-9 ≥ 10 or MADRS ≥ 20 typical)
- Treatment-resistant trials require documented failure of 2+ adequate antidepressant trials
- Bipolar depression must be distinguished — many MDD trials exclude bipolar
- Active suicidal ideation may exclude from some trials (others specifically include it)
- Washout period from current medications typically required (2–4 weeks)
- Comorbid anxiety is commonly allowed but must be secondary in severity
🔄 Bipolar Disorder Trials
Find actively recruiting bipolar disorder clinical trials across the UK
View Bipolar Disorder Trials💭 Depression Trials
Find actively recruiting depression clinical trials across the UK
View Depression (MDD) Trials